Contraception News and Research

Latest Contraception News and Research

STD prevention programs in schools: Mixed outcomes on sexual behaviors

Teaching teens about sexually transmitted infections at school boosts factual knowledge, but does not necessarily translate to increased condom use, according to a new review from the United Kingdom.

26 Feb 2010

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.

22 Feb 2010

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Novartis announced today that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

19 Feb 2010

BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting

BioSante Pharmaceuticals, Inc., will present a LibiGel clinical update at the 2010 Annual Meeting of the International Society for the Study of Women’s Sexual Health (ISSWSH), being held from February 18-20, 2010 in St. Petersburg, Florida.

19 Feb 2010

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

FDA grants approval for Abbott's antiretroviral medication Norvir

Abbott announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir ® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.

11 Feb 2010

Contraceptive sex education and 'empowerment' for ten-year-old children

International Planned Parenthood Foundation's recently released report, "Stand and Deliver: Sex, Health and Young People in the 21st Century," advocates policies that jeopardize the well-being of children's health, the importance of parents and the moral values of our society, Family Research Council said today.

10 Feb 2010

Study indicates women receiving antiretroviral therapy are more likely to become pregnant

In PLoS Medicine this week a study conducted in a multi-country HIV treatment program in sub-Saharan Africa has found that pregnancy rates increase in HIV-infected women after they start antiretroviral therapy (ART).

9 Feb 2010

NPR examines Obama administration's global family planning policies

NPR's "Morning Edition" examines how global family planning fits into the Obama administration's global health policy. "The administration has already restored funding for the United Nations Population ... Fund, which for eight years received no U.S. support. And in his first week, President Obama lifted an executive order that existed in the Reagan and Bush administrations that prohibited U.S.-funded programs from providing information about abortion services," according to NPR.

4 Feb 2010

Public policy implications in abstinence-only programs

Study focused on young African American preteens in an urban area: This is a legitimate public health study and it did show that a certain type of abstinence only program can help some very young adolescents (average age 12) delay sexual initiation for up to 24 months.

3 Feb 2010

Transdermal estrogen therapies: Effective alternatives to oral estrogen and compounded bioidentical hormones

Clinical and experimental evidence suggests that non-patch, transdermal estrogen therapies, such as Divigel® (estradiol gel 0.1%), prescribed for the management of moderate-to-severe hot flashes, including night sweats, associated with menopause are effective alternatives to oral estrogen and compounded bioidentical hormones.

28 Jan 2010

Reproductive coercion and partner violence increase risk of unintended pregnancy

Young women and teenage girls often face efforts by male partners to sabotage birth control or coerce pregnancy - including damaging condoms and destroying contraceptives - and these efforts, defined as "reproductive coercion," frequently are associated with physical or sexual violence, a study by a team of researchers led by UC Davis has found.

25 Jan 2010

Watson Pharmaceuticals provides detailed overview of its global operations at Investor Day meeting in NY

Watson Pharmaceuticals, Inc. today provided a detailed overview of its expanded global operations, enhanced supply chain capabilities and commercial and pipeline developments in its Brand and Generics businesses during an Investor Day meeting held in New York, NY.

22 Jan 2010

UNAIDS chief calls for reduction in MTCT in Africa

UNAIDS Executive Director Michel Sidibe on Monday during a five-day trip in Kenya, called for a drastic reduction in mother-to-child transmission (MTCT) of HIV in sub-Saharan Africa, Capital News reports. "In our continent we still have 400,000 babies born every year with HIV and we know if we are capable of making sure that testing will become available universally to all our pregnant women, (and) that pregnant women also have access to treatment, we will prevent the transmission," Sidibe said (Karong'o, 1/11).

13 Jan 2010

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Antares Pharma, Inc. and the Population Council today announced successful results from a dose-finding Phase 2 trial for a novel contraceptive gel containing the progestin Nestorone and estradiol (NES/E2) utilizing the Antares ATD (advanced transdermal delivery) gel system. Based on this successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialize this novel contraceptive gel.

12 Jan 2010

Obama administration supports Cairo conference goals, Clinton says

Secretary of State Hillary Rodham Clinton on Friday "reiterated the Obama administration's support" for universal access to family planning, improving maternal health care and other goals outlined at the 1995 International Conference on Population and Development Action Plan held in Cairo, Egypt, All Headline News reports.

12 Jan 2010

Health and development groups applaud Clinton speech; call for action

A broad coalition of organizations representing millions of Americans applauded today's statement by Secretary of State Hillary Clinton that the United States unequivocally supports the worldwide consensus that achieving universal access to reproductive health is critical for individual health, family well-being, broader economic development and a healthy planet.

9 Jan 2010

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.

7 Jan 2010

Discovery of inhibitory hormone may yield new treatments for cancer and other diseases

Nearly 10 years after the discovery that birds make a hormone that suppresses reproduction, University of California, Berkeley, neuroscientists have established that humans make it too, opening the door to development of a new class of contraceptive and possible treatments for cancer or other diseases.

23 Dec 2009

SenoRx wins patent infringement case

Hologic, Inc. (Hologic or the Company), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the jury in the patent infringement lawsuit against SenoRx brought by Hologic, Cytyc Corp., and Hologic L.P., Inc. in the U.S. District Court for the Northern District of California has returned a verdict in favor of SenoRx.

22 Dec 2009

Contraception News and Research

Latest Contraception News and Research

STD prevention programs in schools: Mixed outcomes on sexual behaviors

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

FDA grants approval for Abbott's antiretroviral medication Norvir

Contraceptive sex education and 'empowerment' for ten-year-old children

Study indicates women receiving antiretroviral therapy are more likely to become pregnant

NPR examines Obama administration's global family planning policies

Public policy implications in abstinence-only programs

Transdermal estrogen therapies: Effective alternatives to oral estrogen and compounded bioidentical hormones

Reproductive coercion and partner violence increase risk of unintended pregnancy

Watson Pharmaceuticals provides detailed overview of its global operations at Investor Day meeting in NY

UNAIDS chief calls for reduction in MTCT in Africa

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Obama administration supports Cairo conference goals, Clinton says

Health and development groups applaud Clinton speech; call for action

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Discovery of inhibitory hormone may yield new treatments for cancer and other diseases

SenoRx wins patent infringement case

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Contraception News and Research

Latest Contraception News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in